{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-10191"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-10191","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Orally Administered Nanoscale Drug Delivery System for Colorectal Cancer","abstract":"Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To minimize its toxicity, we have developed an orally delivered nanoscale drug delivery system by which Mit-A can be delivered using biocompatible and biodegradable materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the inner core and chitosan (CS) on the outer shell of nanoparticles having an average size of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel which release the payload at the colonic site to target CRC and CSCs thus, contributing to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor burden in an orthotopic CRC mouse model. Taken together, an orally administered nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a promising drug delivery system to target CRC and CSCs with reduced toxicity.","abstract_html":"Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To minimize its toxicity, we have developed an orally delivered nanoscale drug delivery system by which Mit-A can be delivered using biocompatible and biodegradable materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the inner core and chitosan (CS) on the outer shell of nanoparticles having an average size of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel which release the payload at the colonic site to target CRC and CSCs thus, contributing to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor burden in an orthotopic CRC mouse model. Taken together, an orally administered nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a promising drug delivery system to target CRC and CSCs with reduced toxicity.","abstract_has_math":false,"creators":["Shah, Bhavya"],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Graduate School","degree_department":null,"school":null,"contributors":["Subhra Mohapatra, Ph.D.","Shyam Mohapatra, Ph.D.","Eleni Markoutsa, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-03-31T07:00:00Z","date_published":"2020-03-31T07:00:00Z","updated_at":"2026-11-19T08:44:51Z","subjects":["CRC","CSCs","Hydrogel","Mithramycin-A","Nanotechnology","Nanotherapy","Medicinal Chemistry and Pharmaceutics"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/8994","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/8994","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-10191","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Subhra Mohapatra, Ph.D.","Shyam Mohapatra, Ph.D.","Eleni Markoutsa, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Shah, Bhavya"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-03-31T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Graduate School"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["CRC","CSCs","Hydrogel","Mithramycin-A","Nanotechnology","Nanotherapy","Medicinal Chemistry and Pharmaceutics"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/8994"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To minimize its toxicity, we have developed an orally delivered nanoscale drug delivery system by which Mit-A can be delivered using biocompatible and biodegradable materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the inner core and chitosan (CS) on the outer shell of nanoparticles having an average size of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel which release the payload at the colonic site to target CRC and CSCs thus, contributing to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor burden in an orthotopic CRC mouse model. Taken together, an orally administered nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a promising drug delivery system to target CRC and CSCs with reduced toxicity."]},{"key":"dc:title","label":"Title","values":["Orally Administered Nanoscale Drug Delivery System for Colorectal Cancer"]}]}],"canonical_facts":{"dc:contributor":["Subhra Mohapatra, Ph.D.","Shyam Mohapatra, Ph.D.","Eleni Markoutsa, Ph.D."],"dc:creator":["Shah, Bhavya"],"dc:date":["2020-03-31T07:00:00Z"],"dc:description":["Mithramycin-A (Mit-A) is a US Food and Drug Administration (FDA) approved chemotherapeutic agent that is used for the treatment of testicular cancer. According to previous studies, Mit-A has shown promising results in targeting colorectal cancer (CRC) and cancer stem cells (CSCs) which are responsible for a highly invasive and metastatic forms of CRC. The use of Mit-A as chemotherapy is limited in CRC due to its toxicity. To minimize its toxicity, we have developed an orally delivered nanoscale drug delivery system by which Mit-A can be delivered using biocompatible and biodegradable materials. Mit-A nanoparticles were prepared using Poly(lactic-co-glycolic acid) as the inner core and chitosan (CS) on the outer shell of nanoparticles having an average size of 166.66 ± 0.86 nm and were dispersed in alginate/chitosan double crosslinked hydrogel which release the payload at the colonic site to target CRC and CSCs thus, contributing to total cancer therapy. In-vitro and in-vivo results show that oral administration of Mit-A nanoparticles dispersed in hydrogel have a decreased toxicity and can reduce the tumor burden in an orthotopic CRC mouse model. Taken together, an orally administered nanoscale drug delivery system of Mit-A nanoparticles dispersed in the hydrogel is a promising drug delivery system to target CRC and CSCs with reduced toxicity."],"dc:identifier":["https://digitalcommons.usf.edu/etd/8994"],"dc:subject":["CRC","CSCs","Hydrogel","Mithramycin-A","Nanotechnology","Nanotherapy","Medicinal Chemistry and Pharmaceutics"],"dc:title":["Orally Administered Nanoscale Drug Delivery System for Colorectal Cancer"],"thesis:degree_discipline":["Graduate School"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:44:51Z"}